Dr. Jack A. Roth received his MD from Johns Hopkins University. He is a leading researcher in tumor suppressor gene therapy for cancer, and was the first to introduce this novel approach to the clinic. The focus of Dr. Roth’s studies has been the genetic events involved in lung carcinogenesis, and the therapies that might be developed to target them. He and his co-workers were among the first to show that restoration of the function of a single normal tumor suppressor gene could mediate regression of human cancers in vivo. He was the principal investigator for the first tumor suppressor gene therapy clinical trials approved by the National Institutes of Health Recombinant DNA Advisory Committee, and the Food and Drug Administration, after showing the feasibility and efficacy of this treatment in pre-clinical studies. This approach was further validated recently when an adenovirus expressing the p53 tumor suppressor gene became the first gene therapy approved for human use when it was approved by the China State FDA. Dr. Roth and colleagues initiated the first clinical trial using nanoparticles to deliver genes systemically to cancers. Dr. Roth has served as head of the Thoracic Oncology Section of the Surgery Branch of the National Cancer Institute. He is a member of 29 national and international professional associations and serves on ten editorial boards of major clinical and scientific journals, including Clinical Cancer Research, and Cancer Gene Therapy. He is also the author of more than 500 peer-reviewed papers and 1000 total publications. He holds 18 issued patents and is the recipient of numerous and prestigious awards.